BrianAJackson/iStock via Getty Images
- U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved BeiGene's (NASDAQ:BGNE) Brukinsa to treat adult patients with chronic lymphocytic leukemia (CLL) and adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.